Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs

Chun-wei Xu,Lei Lei,Wen-xian Wang,Li Lin,You-cai Zhu,Hong Wang,Li-yun Miao,Li-ping Wang,Wu Zhuang,Mei-yu Fang,Tang-feng Lv,Yong Song

DOI: https://doi.org/10.1016/j.tranon.2020.100791

IF: 4.803

2020-09-01

Translational Oncology

Abstract:Epidermal growth factor receptor (EGFR) exon 19 deletion (E19del) is the most common activating mutation in advanced non–small cell lung cancer (NSCLC) and associates with the sensitivity of EGFR tyrosine kinase inhibitors (TKIs) treatment. However, not all mutant patterns of E19del have been well studied for the limited coverage of regular EGFR mutation testing. Here, we performed a retrospective cohort study of the C-helix E19del in advanced NSCLC patients based on the screening data by the next-generation sequencing (NGS) platform. From May 2012 to December 2019, clinical information and specimen from 7544 consecutive advanced (IIIB/IV) NSCLC patients were collected and screened for EGFR gene mutations by NGS from multicenters in China. The molecular characteristics and responsiveness to first-line EGFR TKIs therapy in NSCLC patients with C-helix E19del were analyzed. The clinical characteristics were also compared between patients with classical E19del and C-helix E19del. Thirty-eight (2.6%) patients with C-helix E19del and 1400 (97.4%) patients with classical E19dels were identified from 1438 patients with E19del. No significant difference in clinical characteristics was observed between the C-helix E19del and classical E19del groups (P > .05), except for histology (P < .001). All 22 patients with C-helix E19del as p.S752_I759del, p.A750_E758del, p.A750_E758delinsP, p.T751_A755delinsNY, p.T751_I759delinsG, p.T751_I759delinsLD, p.T751_I759delinsN, p.T751_L760delinsNL, and p.T751_D761delinsLY reached the best response as partial response rate (72.7%), and the progression-free survival (PFS) was 12.0 months. The PFS after EGFR TKIs in patients with C-helix E19del tended to be longer than patients with classical E19del but has no statistical significance (12.0 months vs 8.5 months, P = .06). The C-helix E19del could be a positive biomarker for predicting response to EGFR TKIs in advanced NSCLC patients. NGS should be the appropriate platform to identify this rare population, especially when patients harbor no actionable driver mutation initially and are reluctant to accept chemotherapy as first-line therapy.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about the molecular characteristics of EGFR exon 19 C - helix region deletion mutation (C - helix E19del) in non - small - cell lung cancer (NSCLC) patients and their clinical response to EGFR tyrosine kinase inhibitors (EGFR TKIs) treatment. Specifically, the study aims to explore the following aspects through a retrospective cohort study: 1. **Molecular characteristics of C - helix E19del**: Understand the distribution and frequency of this specific type of EGFR mutation in NSCLC patients, as well as the specific forms of these mutations. 2. **Comparison between C - helix E19del and classic E19del**: Analyze the differences in clinical features between C - helix E19del and the classic E19del mutation, including the patient's age, gender, smoking history, histological type, etc. 3. **Response of C - helix E19del to EGFR TKIs treatment**: Evaluate the efficacy of NSCLC patients with C - helix E19del after receiving EGFR TKIs treatment, including the partial response rate (PR) and progression - free survival (PFS). 4. **The role of NGS in detecting rare mutations**: Explore the advantages of using next - generation sequencing (NGS) technology in detecting this type of rare EGFR mutation, especially in cases where conventional gene mutation detection methods may miss it. The research background indicates that although EGFR exon 19 deletion (E19del) is one of the most common activating mutations and is related to the sensitivity of EGFR TKIs treatment, the E19del mutation in the C - helix region is relatively rare, and conventional gene mutation detection methods may not fully cover this region. Therefore, through large - scale NGS screening, the researchers hope to more comprehensively understand the clinical significance of this rare mutation. In general, this study aims to fill the research gap of C - helix E19del mutation in NSCLC and provide more evidence for it as a potential biomarker for EGFR TKIs treatment.

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.

Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients.

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and Its Response to EGFR-TKIs

P089 an EGFR KDD Data in the Chinese NSCLC Population and the Response to EGFR-TKIs: A Multicenter Study

Better Survival with Epidermal Growth Factor Receptor Exon 19 Deletion Than with Exon 21 Mutation in Gefitinib-Treated Non-Small Cell Lung Cancer Patients is Due to Differential Inhibition of Downstream Signals

Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer

Real-world Response and Outcomes in Patients with NSCLC with EGFR Exon 20 Insertion Mutations

Structure-based classification and nomogram prediction for differential inhibitor sensitivity of EGFR exon 19 deletions.

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients